Jump to Navigation
Home

Main menu

  • Home
  • News
  • Markets Map
  • Sentiments
  • Topics
  • Data
  • Comments
  • Images
  • Blog
  • About

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • Discussions
  • Mixed messages: Why women and men miscommunicate
  • Put-Write ETF Focuses On Income
  • An offering for religious understanding
  • The last to the party: Investors and flippers competing...
  • Shareholders and the dark art of gaming the tax system
  • Dodgy tax practices dog multinationals
  • Cisco Stepping On The Toes Of IBM And Hewlett-Packard
  • Atco’s Nancy Southern: A firm grip on the reins of the...
  • Saturday Papers
  • Green Gate Fire

    A.P. Pharma: Side Effect Issue With Competitive Drug Is A Huge Positive

    Mon, 07/02/2012 - 07:18 EDT - Seeking Alpha
    • APPA.OB
    • DNDN
    • HGSI
    • Smith On Stocks

    By Smith On Stocks:
    Investment Thesis
    The FDA issued a safety communication on June 29, 2012 further advising physicians on the link of ondansetron (Zofran) to QT interval prolongation; this condition can cause abnormal heart rhythms that in some cases may be life threatening. This follows a previous communication on the same concern on September 11, 2011. Because AP Pharma's (APPA.OB) competitive product in development, APF530, is not linked to QT interval prolongation, this gives APF530 a meaningful differentiation from ondansetron in terms of safety. In addition, ondansetron can no longer be given as a single 32 mg infusion and will now have to be given in roughly three infusions over a twelve hour period. Some contacts I have spoken with think that these factors will cause a major erosion in ondansetron sales. If their assessment is correct, this could be a huge positive for A.P. Phama as ondansetron currently accounts for one thirdComplete Story »

    • Original article
    • Login or register to post comments
     

    Related

    • ER visits linked to energy drinks doubled since 2007, according to government survey

      SAN FRANCISCO — A new government survey suggests the number of people seeking emergency treatment after consuming energy drinks has doubled nationwide during the past four years, the same period in which the supercharged drink industry has surged in popularity in convenience stores, bars and on college campuses.

    • AP Pharma's APF530 Poised To Return To FDA Review

      By Andrew McDonald:AP Pharma (APPA.PK) intends to resubmit the New Drug Application (NDA) for APF530 in 1H12 after working quietly and diligently on addressing all the issues raised in a March 2010 complete response letter (CRL), which the FDA issued in response to the original NDA filing (May 2009).

    • FDA Considers Yanking Abbott's Diet Pill

      Pharmalot submits: Eight months after their European counterparts told doctors to stop prescribing Abbott Labs’ (ABT) Meridia diet pill, the FDA will now ask an advisory panel meeting this Wednesday whether the drug should be withdrawn from the US market.

    • Johnson & Johnson Gets A Big Win As FDA Approves New Diabetes Drug

      By Trefis: Johnson & Johnson's (NYSE:JNJ) received a major boost as its blockbuster potential type 2 diabetes drug, Invokana (commonly known as Canagliflozin), was granted FDA approval. [1] The approval marks JNJ's first entry into the huge diabetes market.

    • A.P. Pharma: PDUFA Date On APF530 Looms And I Am A Buyer

      By Smith On Stocks: Investment Opinion and Background

    • US warns of liver damage with heart drug

      A heart drug by French pharmaceutical giant Sanofi-Aventis has been linked to liver damage in some patients, two of whom had to receive transplants, the US Food and Drug Administration said Friday.Dronedarone, marketed as Multaq, was approved in 2009 and has been prescribed at least 492,000 times to people in the United States for treating abnormal heart rhythm.The FDA issued its warning to the public and to health professionals, saying labels to the medication would be changed to advise of possible liver dangers.

    • Drug Linked To Deaths In US Military Kills London Marathoner Mid-Run

      A young runner who collapsed and died during the London marathon had "significant" levels of a banned amphetamine-like fatburning supplement in her system, an inquest has heard. Claire Squires, 30, suffered a cardiac arrest outside Buckingham Palace, where she was treated in a medical tent before being rushed to hospital.

    • Vibex MTX: The Cherry On Top Of The Antares Investment Story

      By Smith On Stocks: Investment Thesis

    • Arena’s Diet Pill May Encounter Yet Another Issue: Heart Valve Disease

      Pharmalot submits: When the FDA issued a complete response letter last month for the Arena Pharmaceutical (ARNA) diet pill, the agency cited a few reasons: pending results of a trial in 604 patients with diabetes, concerns that the pill may cause tumors in rats and efficacy was marginal (look here).

    • Eurozone Retail Sales Drop 8th Month; Italy, France are Down; Germany Retail Sales Up, Outlook Down

      German retail sales bounced back for the second month, but not enough to prevent the aggregate eurozone sales from falling for the eighth consecutive month. Summary of June findings:

    Latest

    The last to the party: Investors and flippers competing for small amount of inventory.
    The last to the party: Investors and flippers...
    Forget Prayer, It's Lamb Slaughter Time: A Rational Man's Response To All Time High Gold Shorts
    Forget Prayer, It's Lamb Slaughter Time: A...

    User login

    • Create new account
    • Request new password
    • Click on the icon to sign in with your social network login or enter your Bullfax.com login

    Our Blog

    • Tata Steel, ECB, China’s car market and European Corporate Tax in Our News for Today 05/24/2013
    • Pandora: the charm might fade away
    • Japanese Market, Indian Rupee, China’s Stocks and Oil Prices in Our Daily Round-Up for 05/23/2013

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 1649.60 -0.06% FTSE: 6654.34 -0.64% Nikk.: 14612.45 0.88% DAX: 8305.32 -0.56% HSI: 22618.67 -0.23% FX: EUR/GBP: 1.1694 USD/EUR: 1.2935 JPY/USD: 101.175 Commodities: Gold: 1386.60

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • Discussions